[144] GATX Corporation SEC Filing

Rhea-AI Filing Summary

On 31 Jul 2025 The Clorox Company (NYSE: CLX) filed a Form 8-K to furnish its fiscal Q4 and full-year 2025 results under Item 2.02 and to provide supplemental information under Item 7.01. While the filing references the earnings press release (Exhibit 99.1) and detailed schedules (Exhibit 99.2), no quantitative data (revenue, EPS, margin, guidance) are included in the body of the report itself; investors must review the exhibits for specifics.

No other corporate events—such as acquisitions, restructurings, capital actions or leadership changes—are disclosed. The document’s primary purpose is to place the earnings materials into the public domain and satisfy SEC disclosure requirements; market impact therefore depends entirely on the financial figures contained in the attached exhibits, not on the 8-K narrative.

Insights

Sell-Side Equity Analyst

TL;DR: Procedural 8-K—earnings exhibits attached, no numbers inside; impact depends on figures not shown here.

Because the core financial metrics are only embedded in Exhibits 99.1 and 99.2, the filing itself offers no basis to revise estimates or valuation. Investors must consult the press release to assess sales trends, margins, pricing or FY26 guidance. From a trading perspective, the 8-K per se is neutral; price reaction will hinge on the separate earnings data.

Corporate Governance Specialist

TL;DR: Standard compliance filing; demonstrates timely disclosure, no governance red flags detected.

Clorox met its reporting obligations by promptly furnishing the earnings release via Form 8-K. Inclusion of supplemental schedules improves transparency. There are no indications of restatements, internal-control issues, or unusual board actions. Accordingly, governance risk remains unchanged and impact is minimal.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	2200	335687.66	35600000	07/31/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/31/2025	Exercise of options under a registered plan	Issuer			2200	07/31/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

When did Clorox (CLX) file its latest Form 8-K?

The company filed the Form 8-K on July 31, 2025.

What items are covered in Clorox’s July 31 2025 Form 8-K?

The filing covers Item 2.02 (Results of Operations) and Item 7.01 (Regulation FD disclosure).

Where can investors find Clorox’s Q4 FY25 financial figures?

Detailed numbers are in Exhibit 99.1 (press release) and Exhibit 99.2 (supplemental tables) attached to the 8-K.

Did the 8-K report any mergers, leadership changes or legal issues?

No. The document only furnishes earnings information; it reports no other material corporate events.